COMP <GO>
CME vs BRK-A // EV/EBITDA & P/E VALUATION
CME Group Inc. (NASDAQ) VS. Berkshire Hathaway Inc. (Class A) (NYSE) • 15-METRIC TALLY: CME 7
— BRK-A 5
▲ EV/EBITDA & P/E VALUATION LEADER: BRK-A
LAST: $303.14 (+2.27%) • MKT CAP: $106.10B
valuation
40.2x
LAST: $815,600.00 (-0.23%) • MKT CAP: $1.20T
valuation
9.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CME VS. BRK-A)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CME | BRK-A | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.50% | 11.47% | -7.97 | BRK-A | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 40.2x | 9.7x | +30.52 | BRK-A | /valuation <GO> |
| Free Cash Flow Yield | 3.95% | 2.09% | +1.86 | CME | /fcf-yield <GO> |
| Operating Margin | 64.90% | 27.80% | +37.10 | CME | /operating-margins <GO> |
| Net Profit Margin | 62.50% | 22.30% | +40.20 | CME | /net-margins <GO> |
| Revenue Growth (YoY) | 6.40% | 3.93% | +2.47 | CME | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 3.71% | 0.00% | +3.71 | CME | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | CME | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.6 | 68.1 | -10.50 | BRK-A | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.13 | -0.12 | BRK-A | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.3x | 24.3x | -0.04 | CME | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $106.10B | $1.20T | -$1.10T | BRK-A | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CME REV | BRK-A REV | CME GROSS % | BRK-A GROSS % | CME FCF | BRK-A FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.52B | $247.24B | — | — | $4.19B | $25.04B |
| FY 2024 | $6.13B | $249.71B | — | — | $3.60B | $11.62B |
| FY 2023 | $5.58B | $254.91B | — | — | $3.20B | $37.73B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CME // BETA 1.01
BRK-A // BETA 1.13